Lilly adds $450 million to its North Carolina plant as an obesity decision nears

Eli Lilly said on January 24, 2023, that it would invest an additional $450 million and add at least 100 jobs at its manufacturing site in Research Triangle Park, North Carolina ^[1][2]. The money will pay for more parenteral filling, device assembly, and packaging capacity for the company's incretin products, the class of drugs that includes tirzepatide ^[1].

The investment comes as Lilly works to catch up with demand. In December 2022, the FDA added both Trulicity and Mounjaro to its drug shortage list ^[2]. Mounjaro, the brand name for tirzepatide, was approved for type 2 diabetes in May 2022, and Lilly said it expected a decision on an obesity indication for the same drug sometime in 2023 ^[2]. That approval later became Zepbound, though this announcement predates that name.

Lilly said the new spending builds on roughly $4 billion committed to North Carolina manufacturing since 2020, including $1.7 billion already earmarked for developing and expanding the Research Triangle Park site ^[1][2]. The company expected initial production there to begin in 2023, with FDA inspections in preparation ^[1]. The jobs tied to this specific expansion phase would not fully materialize until the plant is completely operational in 2027 ^[1][2].

Executive vice president Edgardo Hernandez said Lilly aimed to double its incretin manufacturing capacity by the end of 2023, a goal first stated in November 2022, and called the new investment "key to ensuring even more patients will have access to medicines they need in the future" ^[1][2]. Wall Street was already betting heavily on Mounjaro's growth: Goldman Sachs analyst Chris Shibutani estimated in a note the same week that the drug could generate $2.3 billion in sales in 2023 and as much as $27 billion at its peak in 2032, according to Reuters ^[2]. Lilly's diabetes drug Trulicity, by comparison, brought in $5.5 billion in sales through the first nine months of 2022 ^[2].

Why it matters for patients

For people already prescribed Mounjaro, or waiting to see whether a similar drug would be approved for weight loss, manufacturing capacity was directly tied to whether they could actually fill a prescription. The FDA shortage listing in December 2022 meant some patients were already having trouble finding doses at pharmacies ^[2]. A new plant does not fix a shortage overnight — Lilly said the North Carolina expansion would not be fully operational until 2027, years after this announcement ^[1][2].

The investment also signals how much manufacturing scale matters in this drug category. Because these medicines are injectable and require specialized filling and device assembly, building new capacity takes years, not months. That lag helps explain why supply problems for tirzepatide and semaglutide persisted well after this 2023 announcement, even as demand kept climbing.

What happens next

At the time of this announcement, Lilly said it expected the FDA to decide on an obesity indication for tirzepatide sometime in 2023 ^[2]. The company also said it anticipated starting initial production at the Research Triangle Park site in 2023, pending FDA inspections ^[1]. Full operation of this expansion phase, including the new jobs, was not expected until 2027 ^[1][2]. The sources reviewed for this story do not specify the exact date the obesity approval was granted or confirm whether the 2023 capacity-doubling goal was met on schedule.